Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.

导出 OA

翻译打印收藏纠错

第一作者： Rosa,Nadal

第一单位： Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

作者： Rosa,Nadal ^[1] ; Hua-Ling,Tsai ^[1] ; Victoria J,Sinibaldi ^[1] ; Channing J,Paller ^[1] ; Emmanuel S,Antonarakis ^[1] ; Sammuel R,Denmeade ^[1] ; Michael A,Carducci ^[1] ; Mario A,Eisenberger ^[1]

作者单位： Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. ^[1]

关键词 androgen receptor castration-resistant prostate cancer enzalutamide and abiraterone prognostic factors

主题词老年人(Aged);雄激素拮抗药(Androgen Antagonists);疾病恶化(Disease Progression);人类(Humans);男(雄)性(Male);中年人(Middle Aged);预后(Prognosis);前列腺特异抗原(Prostate-Specific Antigen);受体, 雄激素(Receptors, Androgen);回顾性研究(Retrospective Studies);治疗结果(Treatment Outcome)

DOI 10.1002/pros.23141

PMID 26689606

发布时间 2023-01-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览50

The Prostate

2016年76卷5期

512-20页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.

The Prostate

相似文献

The Prostate

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.

The Prostate

相似文献

The Prostate

相关期刊

检索历史清除